Blanket Purchase Agreement 36F79720D0148-36E79720A0013
Award Date
6/16/20
Last Date to Order
6/15/25
Federal Agency
National Acquisition Center
Awardee
Harmony Biosciences LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
Harmony Biosciences LLC, a pharmaceutical company specializing in rare neurological diseases and sleep disorders, holds a multiple award Federal Supply Schedule (FSS-61-IB) contract for Pharmaceuticals and Drugs with the U.S. Department of Veterans Affairs (VA). Under this contract, Harmony Biosciences has been awarded a $5 million Blanket Purchase Agreement (BPA) by the VA National Acquisition Center to provide its WAKIX (pitolisant) medication, which treats excessive daytime sleepiness and...
The Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) to Jazz Pharmaceuticals, Inc., a global biopharmaceutical company, to provide specialty pharmaceutical products such as Xyrem, Xywav, and sodium oxybate formulations. The BPA, valued at up to $150 million, allows the VA to efficiently procure needed medications to support healthcare services for veterans at VA medical facilities nationwide....
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency of the U.S. government, to Vanda Pharmaceuticals Inc. (Vanda) on October 26, 2022. The single-award BPA has a ceiling value of $3,069,780 and a period of performance through August 31, 2024. The BPA is for the procurement of Hetlioz (tasimelteon), a medication used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis Syndrome. Vanda is the manufacturer of...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Vanda Pharmaceuticals Inc. (Vanda) on September 6, 2024. The BPA has a ceiling value of $3,753,465.00 and a period of performance through September 5, 2025. The primary product being procured under this BPA is Hetlioz (tasimelteon), a medication used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis...
The U.S. Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) worth up to $2,500,000 to Amneal Pharmaceuticals of New York, LLC, a for-profit limited liability company that manufactures pharmaceutical products. The BPA is for the provision of the generic drug sodium oxybate, which is used to treat narcolepsy. Amneal Pharmaceuticals holds several indefinite delivery vehicle (IDV) contracts with federal agencies, including a 5-year, $1,700,000 Federal Supply...
The Department of Veterans Affairs National Acquisition Center awarded a Blanket Purchase Agreement (BPA) to Jazz Pharmaceuticals, Inc. for the delivery of specialty pharmaceutical products, primarily the sleep disorder medication Xyrem. The $150 million BPA is issued under Jazz Pharmaceuticals' Pharmaceuticals and Drugs Federal Supply Schedule (FSS) contract, allowing the VA to efficiently procure needed medications for its healthcare facilities. Four task orders worth up to $717,519 have...
The Federal Supply Schedule contract (V797D70102) held by Vanda Pharmaceuticals Inc. (Vanda) is for the provision of pharmaceutical products, primarily the drug Hetlioz (tasimelteon), to the U.S. Department of Veterans Affairs (VA). Hetlioz is used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis Syndrome, conditions that significantly impact many veterans. Vanda has consistently received delivery order contracts and Blanket Purchase Agreements (BPAs) from...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs National Acquisition Center to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and related products. The $3.1 million single-award contract establishes an Indefinite Delivery Vehicle (IDV) for the procurement of orexin inhibitors, a class of sleep-regulating medications, over a one-year base period with four option years. This BPA aims to ensure the availability of...
Hikma Pharmaceuticals USA Inc., a foreign-owned, for-profit pharmaceutical manufacturer, holds a $216 million Federal Supply Schedule contract (FSS-61-IB) with the Department of Veterans Affairs (VA) for the procurement of pharmaceuticals and drugs. This multiple-award, unrestricted Indefinite Delivery Vehicle (IDV) enables Hikma to provide a wide range of pharmaceutical products, including injectable solutions, tablets, and specialized medications, to military treatment facilities, VA...
The National Acquisition Center, a civilian federal agency, has awarded a single-award Blanket Purchase Agreement (BPA) to Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals, for the procurement of the controlled substance sodium oxybate. The contract has a ceiling value of $38,500,000 and a period of performance through February 6, 2026. Hikma Pharmaceuticals USA Inc. is a foreign-owned, for-profit pharmaceutical manufacturer registered in the System for Award...